Eileen Parkes
MB BCh, Ba(O) (Hons), MRCP (Onc), PhD
ASSOCIATE PROFESSOR, INNATE TUMOUR IMMUNOLOGY, Group leader
- Consultant Medical Oncologist, Early Phase Trials
RESEARCH SUMMARY
- Understand resistance mechanisms to immune-targeting treatments in cancer;
- Characterise the role of the interaction of chromosomal instability and DNA repair deficiency with immune activation in tumour initiation, progression and response.
- Study tumour microenvironment, fibroblasts and extracellular matrix in chromosomally unstable cancers.
In the Parkes Lab we study intrinsic inflammatory pathways in cancer. These are important immune pathways, present in all cells, that act as emergency response pathways to viral infection. However, in cancer, these pathways can be rewired and hijacked by the tumour to promote growth, invasion and metastasis.
Recent publications
-
Redefining PD1 as a guardian of stem-like T cells.
Journal article
Jackson M. and Parkes EE., (2024), Nat Rev Immunol
-
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.
Journal article
Jackson A. et al, (2024), The Lancet. Oncology, 25, 1476 - 1486
-
A retrospective analysis of the validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries
Journal article
Jackson A. et al, (2024), The Lancet Oncology
-
Targeting mitotic regulators in cancer as a strategy to enhance immune recognition.
Journal article
Gregorczyk M. and Parkes EE., (2023), DNA repair, 132
-
Non-cell-autonomous cancer progression from chromosomal instability.
Journal article
Li J. et al, (2023), Nature, 620, 1080 - 1088